1 / 21

Ernest T. Andalcio Executive Director, Site Head Informatics Pfizer Global Research & Development April 10, 2003

Internet2 & Pharma Industry National Priorities for Transforming Healthcare Quality Report - implications for patient safety and internet applications. Ernest T. Andalcio Executive Director, Site Head Informatics Pfizer Global Research & Development April 10, 2003. Intro.

Solomon
Télécharger la présentation

Ernest T. Andalcio Executive Director, Site Head Informatics Pfizer Global Research & Development April 10, 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Internet2 & Pharma IndustryNational Priorities for Transforming Healthcare Quality Report - implications for patient safety and internet applications Ernest T. Andalcio Executive Director, Site Head Informatics Pfizer Global Research & Development April 10, 2003

  2. Intro • Ernest Andalcio - Executive Director - Ann Arbor Labs • With Pfizer for 5 years • before that Bristol-Myers Squibb, Johnson & Johnson and Procter & Gamble • Responsible for mobilizing the talents of IT staff to identify, design, develop and implement robust technology solutions enabling delivery of scientific excellence, and for promoting best practices, fostering IT knowledge-sharing and exploring innovative new technologies

  3. Intro • Challenges for Pharma Industry • Opportunities • Share some Learnings

  4. Topics/Contents • Pharmaceutical Industry • Challenges • Opportunities • Learnings

  5. Pfizer Research & Development • Largest privately funded biomedicalresearch organization • Seven major research sites • 2002 R & D investment of $5.3 billion • Count on a few new medicines to reachthe market each year • 4 filings planned for 2003 • Target of 20 filings in next 5 years • Mission…”We will be the most consistently productive R&D organization in the industry.”

  6. Topics/Contents • Pharmaceutical Industry • Challenges • Opportunities • Learnings

  7. Challenges in our Industry • Balancing • Patient needs • Medicine • Patents • New Regulations • Profitability • Risk • Social responsibility • Shareholder expectations

  8. Clinical Trials Require More Patients Worldwide Industry Number of Patients per NCE Source: Parexel Pharmaceutical R&D Statistical Sourcebook 2001; Centerwatch, An Industry in Evolution 2001

  9. Challenges - the long road to a new medicine & how Internet2solutions could one-day help the process Registration Full Development Exploratory Development Discovery

  10. Complex Disease Targets Poor Absorption • Not Sufficiently Selective Too Long in Body • Competition Adverse Reactions Side Effects Unsafe • Low Levels in Body Unstable Not Effective Enough Impractical To Make Challenges -R&D Attrition (why new chemical entities fail) Most Compounds Do Not Become Medicines

  11. Pharmaceutical Technology in Action Gather, analyze and present valuable and timely information to therapeutic project teams for high-priority targets. Use information to help identify novel, high quality targets that may be pursued by the therapeutic project teams. • Data Mining • Sequence Analysis • Information Storage/Retrieval (Database) • Information Presentation

  12. The Challenge… • Biology: The Target • Select the disease-related protein • Understand its function and role • Chemistry: The Compound • Optimize the potency • Avoid adverse pharmacokinetics • Avoid adverse toxic effects

  13. Topics/Contents • Pharmaceutical Industry • Challenges • Opportunities • Learnings

  14. Opportunities - The Future of Medicine • Freedom from heart disease • A full, normal life for diabetics • Preserving the antibiotic miracle • Taking the fear out of cancer • Eliminating frailty in the elderly • Preventing Alzheimer’s disease

  15. Opportunities - The Future of Medicine • Central Nervous System • Diabetes • Women’s Health • Cardiovascular Disease • HIV/AIDs • Urogenital • Pulmonary 20 new filings in next 5 years

  16. Opportunities - Pharma Informatics • Increase productivity • Seek different ways of working to increase the number of medicines that make it to full development annually • Enable new business processes: Improve data/information for timely decision-making • Leverage Scale • Take advantage of Global Capacity • Maximize use of Best Practices: Quality and Architecture of systems used

  17. Topics/Contents • Pharmaceutical Industry • Challenges • Opportunities • Learnings

  18. Learnings - Opportunities for Internet2 to make it happen • Due to the nature of our business - research - enabling technologies like Internet2 aid internal global execution of the R&D process • E.g. “Flipping through” large, secure files (e.g. x-ray images) to spot changes in size of tumors • Pfizer does global R&D, however, due to the nature of our business – highly proprietary – it is a largely secure intranet environment: • though we accept information from outside vendors using “safe zones” technologies

  19. Learnings - Opportunities for Internet2 to make it happen • Enabling new business processes • Streamlined Discovery & Development processes • Improved data/information for more timely (real-time) decision-making (Hi bandwidth human interactions! “Charles Yun”) • First-time • Better • Earlier • Enabling Digital Science“David G. Messerschmidt”

  20. Summary • Pharma Industry (Challenges/Opportunities) • Pharmaceutical R&D processes • Internet2… can enable real-time analysis, dialogue and … “discovery” of new medicines

  21. QUESTIONS? Ernest.Andalcio@Pfizer.com

More Related